Modelling of anti-tumour immune response: Immunocorrective effect of weak centimetre electromagnetic waves

We formulate the dynamical model for the anti-tumour immune response based on intercellular cytokine-mediated interactions with the interleukin-2 (IL-2) taken into account. The analysis shows that the expression level of tumour antigens on antigen presenting cells has a distinct influence on the tumour dynamics. At low antigen presentation, a progressive tumour growth takes place to the highest possible value. At high antigen presentation, there is a decrease in tumour size to some value when the dynamical equilibrium between the tumour and the immune system is reached. In the case of the medium antigen presentation, both these regimes can be realized depending on the initial tumour size and the condition of the immune system. A pronounced immunomodulating effect (the suppression of tumour growth and the normalization of IL-2 concentration) is established by considering the influence of low-intensity electromagnetic microwaves as a parametric perturbation of the dynamical system. This finding is in qualitative agreement with the recent experimental results on immunocorrective effects of centimetre electromagnetic waves in tumour-bearing mice.

[1]  A. Ochab-Marcinek,et al.  Population growth and control in stochastic models of cancer development , 2004, q-bio/0403041.

[2]  W. Solbach,et al.  T‐T Cell Interactions during Cytotoxic T Lymphocyte (CTL) Responses: T Cell Derived Helper Factor (Interleukin 2) as a Probe to Analyze CTL Responsiveness and Thymic Maturation of CTL Progenitors , 1980, Immunological reviews.

[3]  S. Cleary,et al.  In vitro lymphocyte proliferation induced by radio-frequency electromagnetic radiation under isothermal conditions. , 1990, Bioelectromagnetics.

[4]  Wenhong Zhou,et al.  Signal transduction in T helper cells: CD4 coreceptors exert complex regulatory effects on T cell activation and function. , 2004, Current issues in molecular biology.

[5]  V. Voeikov.  Biological Significance of Active Oxygen-Dependent Processes in Aqueous Systems , 2006 .

[6]  C. Giachino,et al.  Melanocyte-specific, cytotoxic T cell responses in vitiligo: the effective variant of melanoma immunity? , 2005, Pigment cell research.

[7]  P Hogeweg,et al.  Macrophage T lymphocyte interactions in the anti-tumor immune response: a mathematical model. , 1985, Journal of immunology.

[8]  S. Rosenberg,et al.  Cancer immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes. , 1986, Annual review of immunology.

[9]  D. Wodarz,et al.  Does programmed CTL proliferation optimize virus control? , 2005, Trends in immunology.

[10]  S. Heegaard,et al.  Establishment and characterization of human uveal malignant melanoma xenografts in nude mice , 2003, Melanoma research.

[11]  S. Ferrone,et al.  Multiple defects of the antigen-processing machinery components in human neuroblastoma: immunotherapeutic implications , 2005, Oncogene.

[12]  Nicola Bellomo,et al.  A Survey of Models for Tumor-Immune System Dynamics , 1996 .

[13]  John B. Shoven,et al.  I , Edinburgh Medical and Surgical Journal.

[14]  Emmanuel Beaudoing,et al.  Size Estimate of the αβ TCR Repertoire of Naive Mouse Splenocytes1 , 2000, The Journal of Immunology.

[15]  Josep M. Guerrero,et al.  Melatonin enhances IL-2, IL-6, and IFN-gamma production by human circulating CD4+ cells: a possible nuclear receptor-mediated mechanism involving T helper type 1 lymphocytes and monocytes. , 1997, Journal of immunology.

[16]  A. Perelson,et al.  Nonlinear dynamics of immunogenic tumors: parameter estimation and global bifurcation analysis. , 1994, Bulletin of mathematical biology.

[17]  D. Kirschner,et al.  A mathematical model of tumor-immune evasion and siRNA treatment , 2003 .

[18]  Mark A J Chaplain,et al.  Mathematical modelling of the spatio-temporal response of cytotoxic T-lymphocytes to a solid tumour. , 2004, Mathematical medicine and biology : a journal of the IMA.

[19]  H. Band,et al.  Hsp72-mediated augmentation of MHC class I surface expression and endogenous antigen presentation. , 1998, International immunology.

[20]  D. Schwartzentruber.  In vitro predictors of clinical response in patients receiving interleukin‐2-based immunotherapy , 1993, Current opinion in oncology.

[21]  L. Norton.  A Gompertzian model of human breast cancer growth. , 1988, Cancer research.

[22]  J. Davies,et al.  Molecular Biology of the Cell , 1983, Bristol Medico-Chirurgical Journal.

[23]  J. Trempe.  Molecular biology of the cell, 3rd edition Bruce Alberts, Dennis Bray, Julian Lewis, Martin Raff, Keith Roberts and James D. Watson, Garland Publishing, 1994, 559.95 (xiii + 1294 pages), ISBN 0-815-31619-4 , 1995, Trends in Endocrinology & Metabolism.

[24]  S. Rosenberg,et al.  Treatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin 2. , 1994, JAMA.

[25]  D. Leibfritz,et al.  Free radicals and antioxidants in normal physiological functions and human disease. , 2007, The international journal of biochemistry & cell biology.

[26]  Nikolai Nikolaevich Kositsky,et al.  Influence of High-frequency Electromagnetic Radiation at Non-thermal Intensities on the Human Body (A review of work by Russian and Ukrainian researchers) , 2001 .

[27]  E. Stoelben,et al.  Immunotherapy of metastatic melanoma with interferon-alpha and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions. , 1994, European journal of cancer.

[28]  Stephanie Forrest,et al.  A stochastic model of cytotoxic T cell responses. , 2004, Journal of theoretical biology.

[29]  Harold P. de Vladar,et al.  Letter to the EditorDynamic response of cancer under the influence of immunological activity and therapy , 2006 .

[30]  D. Kirschner,et al.  Modeling immunotherapy of the tumor – immune interaction , 1998, Journal of mathematical biology.

[31]  Magdy F. Iskander,et al.  An Empirical Formula for Broad-Band SAR Calculations of Prolate Spheroidal Models of Humans and Animals , 1979 .

[32]  Mark A. J. Chaplain,et al.  Mathematical Modelling of Spatio-temporal Phenomena in Tumour Immunology , 2006 .

[33]  M. Nowak,et al.  Oncogenes, anti-oncogenes and the immune response to cancer : a mathematical model , 1992, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[34]  R. Reiter,et al.  Melatonin in Relation to Cellular Antioxidative Defense Mechanisms , 1997, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[35]  D. Longo,et al.  Phase I study of subcutaneously administered interleukin-2 in combination with interferon alfa-2a in patients with advanced cancer. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  R. Lefever,et al.  A kinetic approach to the immunology of cancer: stationary states properties of effector-target cell reactions. , 1978, Journal of theoretical biology.

[37]  Alan S. Perelson,et al.  Recruitment Times, Proliferation, and Apoptosis Rates during the CD8+ T-Cell Response to Lymphocytic Choriomeningitis Virus , 2001, Journal of Virology.

[38]  H J Bakker,et al.  Delocalization of Protons in Liquid Water , 2002, Science.

[39]  Stephen J. Merrill,et al.  Foundations of the use of an enzyme-kinetic analogy in cell-mediated cytotoxicity☆ , 1982 .

[40]  Karol Sikora,et al.  ONCOGENES , 1983, The Lancet.

[41]  K. Lillehei,et al.  Cell-mediated immunotherapy: a new approach to the treatment of malignant glioma. , 2003, Cancer control : journal of the Moffitt Cancer Center.

[42]  J. C. Aledo,et al.  Inhibition of glutaminase expression by antisense mRNA decreases growth and tumourigenicity of tumour cells. , 2000, The Biochemical journal.

[43]  F. McArdle,et al.  Antioxidant micronutrients and gene expression , 1998, Proceedings of the Nutrition Society.

[44]  R. Kennedy,et al.  Interleukin 15 promotes antigen-independent in vitro expansion and long-term survival of antitumor cytotoxic T lymphocytes. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[45]  A. V. Grimstone.  Molecular biology of the cell (3rd edn) , 1995 .

[46]  R. Kaempfer,et al.  Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[47]  J. W. Rooney,et al.  Novel NFAT sites that mediate activation of the interleukin-2 promoter in response to T-cell receptor stimulation , 1995, Molecular and cellular biology.

[48]  S. Kamidono,et al.  Rejection of Mouse Renal Cell Carcinoma Elicited by Local Secretion of Interleukin‐2 , 1996, Japanese journal of cancer research : Gann.